Compare · NTLA vs VNRX
NTLA vs VNRX
Side-by-side comparison of Intellia Therapeutics Inc. (NTLA) and VolitionRX Limited (VNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTLA and VNRX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NTLA is the larger of the two at $2.20B, about 190.4x VNRX ($11.6M).
- Over the past year, NTLA is up 70.5% and VNRX is down 92.0% - NTLA leads by 162.5 points.
- NTLA has been more active in the news (12 items in the past 4 weeks vs 7 for VNRX).
- NTLA has more recent analyst coverage (25 ratings vs 4 for VNRX).
- Company
- Intellia Therapeutics Inc.
- VolitionRX Limited
- Price
- $15.76+0.61%
- $1.36-6.85%
- Market cap
- $2.20B
- $11.6M
- 1M return
- +28.51%
- -45.60%
- 1Y return
- +70.51%
- -92.02%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 2016
- 2015
- News (4w)
- 12
- 7
- Recent ratings
- 25
- 4
Intellia Therapeutics Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
VolitionRX Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Latest NTLA
- Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
- Director Verwiel Frank was granted 9,200 shares, increasing direct ownership by 35% to 35,148 units (SEC Form 4)
- Director Keresty Georgia was granted 9,200 shares, increasing direct ownership by 29% to 41,083 units (SEC Form 4)
- Director Goodman Jesse was granted 9,200 shares, increasing direct ownership by 38% to 33,559 units (SEC Form 4)
- Director Goff Brian was granted 9,200 shares, increasing direct ownership by 39% to 32,609 units (SEC Form 4)
- Director Cohen Fred E was granted 9,200 shares, increasing direct ownership by 4% to 216,653 units (SEC Form 4)
- Director Chase William J was granted 9,200 shares, increasing direct ownership by 7% to 143,893 units (SEC Form 4)
- Director Bhanji Muna was granted 9,200 shares, increasing direct ownership by 34% to 36,403 units (SEC Form 4)
- Intellia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest VNRX
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- VolitionRx Announces Collaboration with Sysmex
- SEC Form 424B5 filed by VolitionRX Limited
- VolitionRx Announces Pricing of $4.6 Million Public Offering
- SEC Form 424B5 filed by VolitionRX Limited
- VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
- SEC Form DEF 14A filed by VolitionRX Limited
- VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
- VolitionRX Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement
- VolitionRX Limited filed SEC Form 8-K: Leadership Update